(Fighting against New Coronary Pneumonia) Comprehensive news: There are currently fewer than 100 cases of Jilin cluster epidemic outbreaks diagnosed in mainland China for 8 consecutive days
China News Agency, Beijing, May 22-The third session of the 13th National People's Congress opened in Beijing on the 22nd. After the national anthem was sung, all the participants stood in silence for one minute in silence to pay tribute to the martyrs and deceased compatriots who died in the new crown pneumonia epidemic. This special link was also established at the opening meeting of the Third Session of the 13th CPPCC National Committee on the 21st.
Overseas imported and local confirmed cases continue to double. Existing confirmed cases are less than 100 cases for 8 consecutive days
The Chinese National Health and Health Commission notified on the 22nd that provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps reported on the 21st that there were 4 newly diagnosed cases, of which 2 were imported overseas, and 1711 confirmed cases were imported overseas. On the same day, 35 new cases of asymptomatic infections were added, no cases were converted to confirmed cases, and 365 cases of asymptomatic infections still under medical observation.
As of 24:00 on the 21st, there are currently 82 confirmed cases in mainland China, with a total of 78,255 discharged and 4,634 dead, and a total of 82,971 confirmed cases reported. A total of 1549 confirmed cases (1063 cases in the Hong Kong Special Administrative Region, 45 cases in the Macau Special Administrative Region and 441 cases in Taiwan) were received.
As of the 21st, mainland China has imported local and overseas confirmed cases for 7 consecutive days, but the number of confirmed cases nationwide has dropped from 100 cases (91 cases) for the first time since May 14 to less than 100 cases for 8 consecutive days .
Jilin cluster epidemic adds 2 more confirmed cases, 2 imported cases in Sichuan are from the Philippines
After a day of interruption on the 20th, the origin was the cluster epidemic in Shulin City, Jilin. On the 21st, two more confirmed cases were added. Jilin City has also become the only source of local cases in mainland China.
According to the Jilin Provincial Health and Health Commission, these two confirmed cases are from people in Fengman District, Jilin City, which are still high-risk areas. They are close contacts of previously confirmed cases, and they are actively screened and tested within the control range to confirm the diagnosis.
According to statistics, as of 24 o'clock on the 21st, the number of confirmed patients in this cluster of epidemic infection chain has been expanded to 45 people, 3 people with asymptomatic infection.
On the 21st, two new imported cases in mainland China were reported by Sichuan Province, and they were all imported from the Philippines. After arriving in Chengdu on the 20th, they received isolation medical observation and dynamic diagnosis and treatment, and were diagnosed on the 21st.
The Chinese Anti-epidemic Medical Experts Group of China Aided Departure Lianhua Qingwen Capsule and other Chinese medicines are effective for the treatment of new coronary pneumonia
The Guangdong Provincial Health Commission said on the 22nd that the Chinese government established by the China National Health Commission and selected by the Guangdong Provincial Health Commission assisted the Peruvian Anti-epidemic Medical Expert Group to take a charter flight to Peru to assist in responding to the new coronary pneumonia epidemic.
Previous official announcements showed that from the outbreak to mid-May, China had sent 21 anti-epidemic medical expert groups to 19 countries.
Guangzhou Institute of Respiratory Health said on the 22nd that the team of academicians Zhong Nanshan confirmed that Lianhua Qingwen Capsules and other Chinese medicines have an inhibitory effect on the cytopathy caused by the infection of New Coronavirus. Academician Zhong Nanshan, together with academicians Zhang Boli, Academician Li Lanjuan and other Chinese and Western medicine clinical experts, started a prospective multicenter randomized controlled clinical trial of Lianhua Qingwen in the treatment of new coronary pneumonia.
The study was conducted in more than 20 hospitals in New China to treat new coronary pneumonia in a targeted manner, using an objective randomized parallel controlled trial design. (Finish)